Find expert answers and community insights on IDNLearn.com. Discover the information you need quickly and easily with our reliable and thorough Q&A platform.
An introduction of recombinant DNA technology to pharmaceutical industry did NOT allow for: a. Improved drug safety b. High level of drug modification/alteration c. Mass-production of the biopharmaceuticals d. Higher average prices of the major biopharmaceuticals e. All of the above were the consequences of the switch to recombinant DNA technology in pharmaceutical industry
Sagot :
We appreciate your contributions to this forum. Don't forget to check back for the latest answers. Keep asking, answering, and sharing useful information. Thank you for trusting IDNLearn.com with your questions. Visit us again for clear, concise, and accurate answers.
